ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
Ferrando L, Vingiani A, Garuti A, Vernieri C, Belfiore A, Agnelli L, Dagrada G, Ivanoiu D, Bonizzi G, Munzone E, Lippolis L, Dameri M, Ravera F, Colleoni M, Viale G, Magnani L, Ballestrero A, Zoppoli G, Pruneri G.
Ferrando L, et al. Among authors: lippolis l.
PLoS Genet. 2023 Jan 3;19(1):e1010563. doi: 10.1371/journal.pgen.1010563. eCollection 2023 Jan.
PLoS Genet. 2023.
PMID: 36595552
Free PMC article.